Clinical trial · no report yet · Phase 3
ESCALADE
A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)
- NCT04529772 ↗
- Active, not recruiting
- Acerta Pharma BV
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| YouTube | 21 | |
| Podcasts | 9 | |
| X threads | 8 |
The trial
ClinicalTrials.gov- Official title
- Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects ≤75 Years With Previously Untreated Non-GCB DLBCL
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- acalabrutinib; placebo; Prednisone; Rituximab; Cyclophosphamide; Vincristine; Doxorubicin
- Arms
- acalabrutinib + R-CHOP · Experimental
- placebo + R-CHOP · Placebo comparator
- Enrollment
- 611
- Primary outcomes
- Progression-free survival (PFS) per the Lugano Classification for NHL in Arm A compared to Arm B
- Sponsor
- Acerta Pharma BV with AstraZeneca
- Start
- Oct 8, 2020
- Primary completion
- Feb 22, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT04529772 · updated Oct 13, 2026